GlassScriptPhysician profile
Alan Edward Zloto
NPI 1770548273
$5,459.63
in general payments reported to CMS, 2019-2025
30 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $1,291 · 2021: $1,416 · 2022: $667 · 2023: $571 · 2024: $728 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $750.68 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $618.30 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $555.33 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $493.56 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.03 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.98 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $315.70 | 2019-2025 | |
| Amarin Pharma, INC. | $309.31 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $259.51 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $220.50 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.06 | 2021-2025 | |
| Abbvie INC. | $145.78 | 2021-2023 | Ubrelvy, Qulipta |
| Eisai INC. | $132.26 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $80.76 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $59.85 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $57.45 | 2019-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $52.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $46.11 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $45.09 | 2020 | |
| Nevro Corp. | $39.18 | 2019-2023 | Senza |
| Idorsia Pharmaceuticals US INC | $33.84 | 2023 | Quviviq |
| Scpharmaceuticals INC. | $27.39 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $24.39 | 2024 | |
| Phathom Pharmaceuticals, INC. | $22.73 | 2024 | Voquezna |
| Philips North America LLC | $19.16 | 2024 | (Ck7) Extended Holter |
| Allergan, INC. | $17.28 | 2019 | |
| Medtronic, INC. | $16.44 | 2021 | |
| Clarus Therapeutics INC. | $13.93 | 2021 | |
| Abbott Laboratories | $13.65 | 2023 | Freestyle Libre 2 |
| Shield Therapeutics INC | $13.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Zloto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.